

CERTIFICATION OF ENROLLMENT

**HOUSE BILL 2251**

Chapter 21, Laws of 2020

66th Legislature  
2020 Regular Session

DISPENSING OF INTERCHANGEABLE BIOLOGICAL PRODUCT--NOTICE TO  
PRACTITIONER--EXPIRATION DATE

EFFECTIVE DATE: June 11, 2020

Passed by the House February 19, 2020  
Yeas 98 Nays 0

LAURIE JINKINS

**Speaker of the House of Representatives**

Passed by the Senate March 3, 2020  
Yeas 49 Nays 0

CYRUS HABIB

**President of the Senate**

Approved March 18, 2020 10:24 AM

JAY INSLEE

**Governor of the State of Washington**

CERTIFICATE

I, Bernard Dean, Chief Clerk of the House of Representatives of the State of Washington, do hereby certify that the attached is **HOUSE BILL 2251** as passed by the House of Representatives and the Senate on the dates hereon set forth.

BERNARD DEAN

**Chief Clerk**

FILED

March 18, 2020

**Secretary of State  
State of Washington**

---

HOUSE BILL 2251

---

Passed Legislature - 2020 Regular Session

State of Washington

66th Legislature

2020 Regular Session

By Representatives Thai and Cody

Prefiled 12/19/19. Read first time 01/13/20. Referred to Committee on Health Care & Wellness.

1 AN ACT Relating to the expiration date for notification of  
2 dispensing an interchangeable biological product; amending RCW  
3 69.41.193; and providing an expiration date.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 **Sec. 1.** RCW 69.41.193 and 2015 c 242 s 4 are each amended to  
6 read as follows:

7 (1) Within five business days following the dispensing of a  
8 biological product, the dispensing pharmacist or the pharmacist's  
9 designee must make an entry of the specific product provided to the  
10 patient, including either the name of the product and the  
11 manufacturer or the federal food and drug administration's national  
12 drug code, provided that the name of the product and the name of the  
13 manufacturer are accessible to a practitioner in an electronic  
14 records system that can be electronically accessed by the patient's  
15 practitioner through:

- 16 (a) An interoperable electronic medical records system;  
17 (b) An electronic prescribing technology;  
18 (c) A pharmacy benefit management system; or  
19 (d) A pharmacy record.

20 (2) Entry into an electronic records system, as described in  
21 subsection (1) of this section, is presumed to provide notice to the

1 practitioner. Otherwise, the pharmacist must communicate to the  
2 practitioner the specific product provided to the patient, including  
3 the name of the product and manufacturer, using facsimile, telephone,  
4 electronic transmission, or other prevailing means.

5 (3) No entry or communication pursuant to this section is  
6 required if:

7 (a) There is no interchangeable biological product for the  
8 product prescribed;

9 (b) A refill prescription is not changed from the product  
10 dispensed on the prior filling of the prescription; or

11 (c) The pharmacist or the pharmacist's designee and the  
12 practitioner communicated before dispensing and the communication  
13 included confirmation of the specific product to be provided to the  
14 patient, including the name of the product and the manufacturer.

15 (4) This section expires August 1, (~~2020~~) 2025.

Passed by the House February 19, 2020.

Passed by the Senate March 3, 2020.

Approved by the Governor March 18, 2020.

Filed in Office of Secretary of State March 18, 2020.

--- END ---